मूलभूत आँकड़े
| CIK | 1712762 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to bioAffinity Technologies, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| September 5, 2025 |
Exhibit 99.1 |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| September 3, 2025 |
Exhibit 99.1 U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA Noninvasive diagnostic can help federal medical system address veterans at higher risk for developing lung cancer SAN ANTONIO, TX – September 3, 2025 – U.S. Medicine, a leading publication for federal healthcare professionals, has featured bioAffinity Te |
|
| September 2, 2025 |
BIOAFFINITY TECHNOLOGIES, INC. SECOND AMENDMENT TO WARRANT Exhibit 4.1 BIOAFFINITY TECHNOLOGIES, INC. SECOND AMENDMENT TO WARRANT THIS SECOND AMENDMENT, dated as of September 2, 2025 (this “Amendment”), to that certain Common Stock Purchase Warrant (“Warrant”), dated as of May 7, 2025, issued by bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) to purchase the number of shares of common stock of the Company as set forth on the signatu |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| September 2, 2025 |
BIOAFFINITY TECHNOLOGIES, INC. FIRST AMENDMENT TO WARRANT Exhibit 4.2 BIOAFFINITY TECHNOLOGIES, INC. FIRST AMENDMENT TO WARRANT THIS FIRST AMENDMENT, dated as of September 2, 2025 (this “Amendment”), to that certain Common Stock Purchase Warrant (“Warrant”), dated as of August 13, 2025, issued by bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) to purchase the number of shares of common stock of the Company as set forth on the signa |
|
| August 29, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025. As filed with the Securities and Exchange Commission on August 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organiza |
|
| August 18, 2025 |
Exhibit 99.1 bioAffinity Technologies Appoints New Members to Board of Directors Financial and Clinical Leaders Provide Significant Expertise for the Company’s Commercial Growth SAN ANTONIO, Texas (August 18, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company advancing noninvasive diagnostics for the early detection of lung cancer and other diseases, today announ |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2025 |
Exhibit 99.1 bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds SAN ANTONIO, Texas (August 13, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into |
|
| August 14, 2025 |
Exhibit 99.2 bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds SAN ANTONIO, Texas (August 14, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced the closing of its prev |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2025 |
Certificate of Designations of Series B Convertible Preferred Stock Exhibit 3.2 BIOAFFINITY TECHNOLOGIES, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware, bioAffinity Technologies, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), in accordance with t |
|
| August 14, 2025 |
Placement Agency Agreement dated August 13, 2025 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT August 13, 2025 bioAffinity Technologies Inc. 33000 Nacogdoches Road, Suite 216 San Antonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $950,000 of unregistered securities of the Company, includi |
|
| August 14, 2025 |
Form of Placement Agent Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 14, 2025 |
Certificate of Amendment to the Certificate of Incorporation Exhibit 3.1 FORM OF CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF BIOAFFINITY TECHNOLOGIES, INC. bioAffinity Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Ce |
|
| August 14, 2025 |
Financial Advisory Agreement dated August 13, 2025 Exhibit 10.4 August 13, 2025 Maria Zannes President and Chief Executive Officer bioAffinity Technologies Inc. 3300 Nacogdoches Suite 216 San Antonio, TX 78217 Re: General Financial Advisory Dear Ms. Zannes, This letter (the “Agreement”) will confirm our understanding that the company known to us as bioAffinity Technologies Inc. (“bioAffinity”, or the “Company”) has engaged WallachBeth Capital LLC |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-41463 bioAffinity |
|
| August 14, 2025 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is entered into and made effective as of August 13, 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). The |
|
| August 14, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of August 13, 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). REC |
|
| August 14, 2025 |
Exhibit 99.1 bioAffinity Technologies Reports Second Quarter 2025 Results CyPath® Lung revenues up 62% year-over-year in first six months of 2025 SAN ANTONIO, Texas (August 14, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported financial results |
|
| August 14, 2025 |
Form of Warrant Inducement Agreement Exhibit 10.3 August 11, 2025 To: Holder of Common Share Purchase Warrants Re: Inducement Offer and Agreement to Exercise Common Share Purchase Warrants Dear Holder: bioAffinity Technologies Inc., a Delaware corporation (the “Company”), is pleased to offer to you the opportunity to exercise the 450,000 Common Stock Purchase Warrants issued to you on August 5, 2024 (with a current exercise price of |
|
| August 14, 2025 |
Exhibit 4.4 BIOAFFINITY TECHNOLOGIES, INC. FIRST AMENDMENT TO WARRANT THIS FIRST AMENDMENT, dated as of August 13, 2025 (this “Amendment”), to that certain Common Stock Purchase Warrant (“Warrant”), dated as of May 7, 2025, issued by bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) to purchase in aggregate [*] shares of common stock of the Company is between the Company and e |
|
| August 14, 2025 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 14, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| August 13, 2025 |
Exhibit 99.1 bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales July Test Volume Surges 72% Over Prior Monthly Average SAN ANTONIO, TX – August 13, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge in commercial sales of its flagship pro |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| July 31, 2025 |
Exhibit 99.1 Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging and Low-Risk Serum Test Results bioAffinity Technologies’ noninvasive sputum test catches rare cancer in time for curative surgery SAN ANTONIO, TX – July 29, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and earl |
|
| July 31, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 25, 2025 Date of Report (Date of earliest event reported) bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| July 23, 2025 |
Exhibit 99.1 Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools bioAffinity Technologies’ noninvasive sputum test flagged difficult-to-diagnose cancer at earliest Stage 1A SAN ANTONIO, TX – July 23, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-s |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| July 22, 2025 |
Exhibit 99.1 Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, TX — July 22, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath |
|
| July 15, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| July 15, 2025 |
Exhibit 99.1 bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic Nearly one-third of world’s smokers live in China, which has one of the highest rates of lung cancer SAN ANTONIO, TX — July 15, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPa |
|
| June 27, 2025 |
As filed with the Securities and Exchange Commission on June 27, 2025. As filed with the Securities and Exchange Commission on June 27, 2025. Registration No. 333-283521 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT NO. 333-283521 UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (Sta |
|
| June 27, 2025 |
As filed with the Securities and Exchange Commission on June 27, 2025. As filed with the Securities and Exchange Commission on June 27, 2025. Registration No. 333-264463 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT NO. 333-264463 UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (Sta |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 30, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 27, 2025 |
Up to $5,801,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275608 PROSPECTUS SUPPLEMENT (To Prospectus dated November 27, 2023) Up to $5,801,000 Shares of Common Stock We have entered into an At-the-Market Issuance Sales Agreement, dated May 22, 2025 (the “Sales Agreement”), with WallachBeth Capital LLC (“WallachBeth” or the “Sales Agent”) relating to the sale of shares of our common stock, par value $ |
|
| May 27, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 27, 2025 |
Exhibit 1.1 BIOAFFINITY TECHNOLOGIES, INC. Common Stock (par value $0.007 per share) At-The-Market Issuance Sales Agreement May 22, 2025 WallachBeth Capital LLC 185 Hudson St Jersey City, NJ 07302 Ladies and Gentlemen: bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with WallachBeth Capital LLC (the “Agent”), as follows: 1. Issuance |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| May 19, 2025 |
Other Events, Shareholder Director Nominations, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 001-41463 bioAffinit |
|
| May 15, 2025 |
Exhibit 99.1 bioAffinity Technologies Reports First Quarter 2025 Results CyPath® Lung sales up 276% year-over-year SAN ANTONIO, Texas (May 15, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three mo |
|
| May 8, 2025 |
Form of Placement Agent Warrant Exhibit 4.3 IN ACCORDANCE WITH FINRA RULE 5110(E), THE REGISTERED HOLDER OF THIS COMMON STOCK PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, OR ASSIGN THIS COMMON STOCK PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS COMMON STOCK PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE, OR HYPOTHECATE THIS COMMON STOCK |
|
| May 8, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT May 5, 2025 bioAffinity Technologies Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of up to $3,239,828.17 of registered securities of the Company, con |
|
| May 8, 2025 |
bioAffinity Technologies Announces Pricing of $3.25 Million Offering Exhibit 99.1 bioAffinity Technologies Announces Pricing of $3.25 Million Offering SAN ANTONIO, Texas (May 6, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a best efforts offering of securities as described below for aggregate gross proceeds to |
|
| May 8, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of May 5, 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). |
|
| May 8, 2025 |
bioAffinity Technologies Announces Closing of $3.25 Million Offering Exhibit 99.2 bioAffinity Technologies Announces Closing of $3.25 Million Offering SAN ANTONIO, Texas (May 7, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has closed its previously announced best efforts offering of securities as described below for aggr |
|
| May 8, 2025 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: May 7, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| May 8, 2025 |
Exhibit 4.2 FORM OF COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: May 7, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (th |
|
| May 8, 2025 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commiss |
|
| May 7, 2025 |
PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-286921 Up to 7,784,904 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,371,346 Shares of Common Stock Warrants to Purchase up to 19,804,687 Shares of Common Stock Placement Agent Warrants to Purchase up to 304,687 Shares of Common Stock Up to 22,480,720 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warran |
|
| May 5, 2025 |
Exhibit 4.19 FORM OF COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: [*], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (the |
|
| May 5, 2025 |
As filed with the Securities and Exchange Commission on May 5, 2025. As filed with the Securities and Exchange Commission on May 5, 2025. Registration No. 333-286921 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No.1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incor |
|
| May 5, 2025 |
Form of Securities Purchase Agreement Exhibit 10.42 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [*], 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS |
|
| May 5, 2025 |
Exhibit 4.20 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| May 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| May 2, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| May 2, 2025 |
Form of Placement Agent Warrant Exhibit 4.21 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 2, 2025 |
WallachBeth Capital, LLC Harborside Financial Plaza 5 185 Hudson St., Suite 1410 Jersey City, NJ 07311 May 2, 2025 VIA EDGAR CORRESPONDENCE U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: bioAffinity Technologies, Inc. Registration Statement on Form S-1 File No. 333-286921 REQUEST FOR ACCELERATION OF EFFECTIVENESS Dear Staff: Pu |
|
| May 2, 2025 |
May 2, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 2, 2025 |
Form of Placement Agency Agreement Exhibit 1.4 PLACEMENT AGENCY AGREEMENT May [*], 2025 bioAffinity Technologies Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of up to $[*] of registered securities of the Company, consisting |
|
| May 2, 2025 |
Form of Securities Purchase Agreement Exhibit 10.42 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [*], 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS |
|
| May 2, 2025 |
Form of Warrant Agent Agreement for the April 2025 Warrants Exhibit 4.22 bioAffinity Technologies, Inc. and VStock Transfer, LLC, as Warrant Agent Warrant Agent Agreement FORM OF WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this “Warrant Agreement”), dated as of [ ], 2025 (the “Initial Exercise Date”) is between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a California limited liability company |
|
| May 2, 2025 |
Exhibit 4.20 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| May 2, 2025 |
As filed with the Securities and Exchange Commission on May 2, 2025. As filed with the Securities and Exchange Commission on May 2, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organization |
|
| May 2, 2025 |
Exhibit 4.19 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission file number 001-4146 |
|
| April 22, 2025 |
bioAffinity Technologies, Inc. 3,013,951 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-286497 PROSPECTUS bioAffinity Technologies, Inc. 3,013,951 Shares of Common Stock This prospectus relates to the resale from time to time of up to 3,013,951 shares of common stock, par value $0.007 per share (the “Common Stock”), of bioAffinity Technologies, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholde |
|
| April 16, 2025 |
April 16, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 15, 2025 |
Phone: (212) 885-5358 Fax: (917) 332-3824 Email: [email protected] April 15, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: bioAffinity Technologies, Inc. Draft Registration Statement (DRS) on Form S-1 Submitted on April 15, 2025 CIK No. 0001712762 Dear Sir or Madam: On behalf of our client, bi |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 15, 2025 |
As confidentially submitted on April [ ], 2025 to the Securities and Exchange Commission. |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| April 11, 2025 |
As filed with the Securities and Exchange Commission on April 11, 2025. As filed with the Securities and Exchange Commission on April 11, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organizat |
|
| April 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| March 31, 2025 |
Amended and Restated Insider Trading Policy of the Registrant Exhibit 19.1 bioAffinity Technologies, Inc. Amended and Restated Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities As Adopted by the Board of Directors on March 27, 2025 I. PURPOSE It is illegal for any employee, officer or director of bioAffinity Technologies, Inc. or any subsidiary thereof (the “Company”) to trade in the securities of the Company wh |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| March 31, 2025 |
Exhibit 99.1 News Release bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 Increased Demand, Expanded Insurance Coverage Drive Record Growth SAN ANTONIO, Texas (March 31, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, |
|
| March 31, 2025 |
Exhibit 4.13 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED bioAffinity Technologies, Inc. (the “Company,” “we,” “us,” and “our”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.007 per share (the “Common Stock”), and trad |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission file number 001-41463 bioAffinity Tech |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| March 7, 2025 |
Exhibit 99.1 News Release bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth ● Proactive steps reinforce bioAffinity Technologies’ laser focus on accelerating CyPath® Lung sales growth in strategic national markets ● Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath® Lung personnel at Company’s subsid |
|
| February 27, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| February 27, 2025 |
Exhibit 10.1 February 25, 2025 To: Holder of Common Share Purchase Warrants Re: Inducement Offer and Agreement to Exercise Common Share Purchase Warrants Dear Holder: bioAffinity Technologies Inc., a Delaware corporation (the “Company”), is pleased to offer to you the opportunity to exercise the [ ] Common Stock Purchase Warrants issued to you on August 5, 2024 (with a current exercise price of $ |
|
| February 27, 2025 |
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million Exhibit 99.1 bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million SAN ANTONIO, Texas (February 25, 2024) – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the |
|
| February 27, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 25, 2025 |
bioAffinity Technologies, Inc. 2,724,230 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-283521 PROSPECTUS SUPPLEMENT NO. 1 (to the prospectus dated December 6, 2024) bioAffinity Technologies, Inc. 2,724,230 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form S-1, effective as of December 6, 2024 (as supplemented or amended from time to tim |
|
| February 25, 2025 |
bioAffinity Technologies, Inc. 1,801,944 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-282045 PROSPECTUS SUPPLEMENT NO. 2 (to the prospectus dated September 19, 2024) bioAffinity Technologies, Inc. 1,801,944 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form S-1, effective as of September 19, 2024 (as supplemented or amended from time to |
|
| February 7, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| January 14, 2025 |
Exhibit 10.1 AMENDMENT NO.2 TO EMPLOYMENT AGREEMENT This Amendment No. 2 effective as of January 10, 2025 (this “Amendment”), to the Employment Agreement, dated February 1, 2015, as amended by the amendment dated July 27, 2023 (the “Agreement”), is entered into by and between bioAffinity Technologies Inc. (the “Company”) and Maria Zannes (the “Employee”). Capitalized terms used herein without defi |
|
| December 23, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| December 20, 2024 |
Exhibit 99.1 GOOD AFTERNOON – I AM EXCITED TO SPEAK WITH YOU TODAY AND DISCUSS OUR PLANS FOR 2025 AS WELL AS REVIEW THE SUCCESS BIOAFFINITY TECHNOLOGIES HAS ENJOYED THIS YEAR. DURING THIS PRESENTATION, CERTAIN FORWARD-LOOKING STATEMENTS REGARDING BIOAFFINITY TECHNOLOGIES, INC.’S CURRENT EXPECTATIONS AND PROJECTIONS ABOUT FUTURE EVENTS WILL BE MADE. GENERALLY, THE FORWARD-LOOKING STATEMENTS CAN BE |
|
| December 9, 2024 |
bioAffinity Technologies, Inc. 2,724,230 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-283521 PROSPECTUS bioAffinity Technologies, Inc. 2,724,230 Shares of Common Stock This prospectus relates to the resale from time to time of up to 2,724,230 shares of common stock, par value $0.007 per share (the “Common Stock”), of bioAffinity Technologies, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholde |
|
| December 4, 2024 |
December 4, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024. As filed with the Securities and Exchange Commission on November 27, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organi |
|
| November 22, 2024 |
1,801,944 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-282045 PROSPECTUS SUPPLEMNT NO. 1 1,801,944 Shares of Common Stock bioAffinity Technologies, Inc. This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form S-1, effective as of September 19, 2024 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333 |
|
| November 22, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-264463 PROSPECTUS SUPPLEMNT NO. 3 4,305,813 Shares of Common Stock underlying Tradeable Warrants and Non-Tradeable Warrants and 55,116 Shares of Common Stock underlying Placement Agent Warrants and Representative’s Warrants bioAffinity Technologies, Inc. This prospectus supplement updates, amends and supplements the prospectus contained in our |
|
| November 22, 2024 |
1,632,000 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-278512 PROSPECTUS SUPPLEMNT NO. 3 1,632,000 Shares of Common Stock bioAffinity Technologies, Inc. This prospectus supplement updates, amends and supplements the prospectus contained in our Amendment No. 1 to Form S-1, effective as of April 15, 2024 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333-278512). C |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 001-41463 bioAff |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2024 |
Exhibit 99.1 bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician offices signed increased 75% over Q2 2024 Reaffirmed $9.6 million 2024 revenue forecast for wholly owned Precision Pathology subsidiary SAN ANTONIO, Texas (November 14 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| October 21, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 21, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT October 18, 2024 bioAffinity Technologies Inc. 3300 Nacogdoches Road, Suite 216 SanAntonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,662,782.20 of registered and unregistered securities of t |
|
| October 21, 2024 |
Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is made as of October 21, 2024, by and between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the beneficial owner of the number of shares of the common stock of the Company set forth o |
|
| October 21, 2024 |
Exhibit 3.1 BIOAFFINITY TECHNOLOGIES, INC. AMENDMENT TO AMENDED AND RESTATED BY-LAWS This Amendment to the Amended and Restated By-laws (the “By-laws”) of bioAffinity Technologies, Inc. (the “Company”), as adopted by the Board of Directors pursuant to Article VIII of said By-laws and Section 10 of the Company’s Certificate of Incorporation, as amended, is effective as of the 17th day of October, 2 |
|
| October 21, 2024 |
2,048,294 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-275608 Prospectus Supplement (to Prospectus dated November 27, 2023) 2,048,294 Shares of Common Stock bioAffinity Technologies, Inc. We are offering 2,048,294 shares of our common stock, $0.007 par value per share (the “common stock”), directly to institutional investors pursuant to this prospectus supplement and the accompanying prospectus. Th |
|
| October 21, 2024 |
Exhibit 99.1 bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement SAN ANTONIO, TX (Oct. 18, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase agreement with i |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| October 21, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 21, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of October 18, 2024, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RE |
|
| October 10, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT bioAffinity Technologies, Inc., for and on behalf of its affiliated corporations (collectively referred to as (the “Company”) and J. Michael Edwards (the “Employee”) hereby enter into this EMPLOYMENT AGREEMENT (“Agreement”) dated as of October 9, 2024 as follows: 1. EMPLOYMENT. The Company shall employ Employee, and Employee shall be employed by the Company upon t |
|
| October 10, 2024 |
Exhibit 99.1 News Release bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer Edwards rejoins the Company after serving as interim CFO SAN ANTONIO, TX (Oct. 10, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that J. Michael Edwards has a |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| October 9, 2024 |
Exhibit 99.1 bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test Noninvasive diagnostic test for lung cancer available to U.S. Veterans, other federal health services patients SAN ANTONIO, TX (Oct. 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-sta |
|
| October 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| September 23, 2024 |
bioAffinity Technologies, Inc. 1,801,944 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-282045 bioAffinity Technologies, Inc. 1,801,944 Shares of Common Stock This prospectus relates to the resale from time to time of up to 1,801,944 shares of common stock, par value $0.007 per share (the “Common Stock”), of bioAffinity Technologies, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholde |
|
| September 17, 2024 |
September 17, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 11, 2024 |
As filed with the Securities and Exchange Commission on September 11, 2024. As filed with the Securities and Exchange Commission on September 11, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organ |
|
| September 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| August 23, 2024 |
Exhibit 10.1 August 21, 2024 bioAffinity Technologies, Inc. Attention: Maria Zannes 3300 Nacogdoches Road, Suite 216 San Antonio, Texas 78217 Dear Maria, Please find below a proposed agreement for services to be provided by J. Michael Edwards, LLC, a Texas Corporation, (“Consultant”), to bioAffinity Technologies, Inc. (“bioAffinity” or “Company”), with regard to finance and accounting support. Sco |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| August 23, 2024 |
Exhibit 99.1 bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO Edwards held CFO position at bioAffinity for nine years, leading Company through successful IPO SAN ANTONIO, TX (Aug. 23, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2024 |
bioAffinity Technologies, Inc. 1,632,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-278512 PROSPECTUS SUPPLEMNT NO. 2 bioAffinity Technologies, Inc. 1,632,000 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus contained in our Amendment No. 1 to Form S-1, effective as of April 15, 2024 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333-278512). C |
|
| August 14, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-264463 PROSPECTUS SUPPLEMNT NO. 2 4,305,813 Shares of Common Stock underlying Tradeable Warrants and Non-Tradeable Warrants and 55,116 Shares of Common Stock underlying Placement Agent Warrants and Representative’s Warrants bioAffinity Technologies, Inc. This prospectus supplement updates, amends and supplements the prospectus contained in our |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 001-41463 bioAffinity |
|
| August 5, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 5, 2024 |
Exhibit 10.3 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is made as of August 1, 2024, by and between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the beneficial owner of the number of shares of the common stock of the Company set forth opp |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| August 5, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 5, 2024 |
Exhibit 99.1 bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million SAN ANTONIO, Texas (August 2, 2024) – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise c |
|
| August 5, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT August 2, 2024 bioAffinity Technologies Inc. 22211 W Interstate 10 Suite 1206 San Antonio, TX 78257 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $450,000 of registered and unregistered securities of the Com |
|
| August 5, 2024 |
Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [*], 2024, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). R |
|
| August 5, 2024 |
Exhibit 10.2 August 2, 2024 To: Holder of Common Share Purchase Warrants Re: Inducement Offer and Agreement to Exercise Common Share Purchase Warrants Dear Holder: bioAffinity Technologies Inc., a Delaware corporation (the “Company”), is pleased to offer to you the opportunity to exercise the Common Stock Purchase Warrants issued to you on March 8, 2024 (with a current exercise price of $1.64 per |
|
| August 5, 2024 |
360,000 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-275608 Prospectus Supplement (to Prospectus dated November 27, 2023) 360,000 Shares of Common Stock bioAffinity Technologies, Inc. We are offering 360,000 shares of our common stock, $0.007 par value per share (the “common stock”), directly to an institutional investor pursuant to this prospectus supplement and the accompanying prospectus. The |
|
| August 2, 2024 |
bioAffinity Technologies, Inc. 1,632,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-278512 PROSPECTUS SUPPLEMENT NO. 2 (to the prospectus dated April 15, 2024) bioAffinity Technologies, Inc. 1,632,000 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus contained in our Amendment No. 1 to Form S-1, effective as of April 15, 2024 (as supplemented or amended from time to time, the “Pro |
|
| July 9, 2024 |
Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 9, 2024 Date of Report (Date of earliest event reported) bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commiss |
|
| July 9, 2024 |
Exhibit 99.1 bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung Sales of CyPath® Lung tests continue to accelerate as sales team expands customer base of pulmonology practices SAN ANTONIO, TX (July 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stag |
|
| June 5, 2024 |
Exhibit 10.1 BIOAFFINITY TECHNOLOGIES, INC. 2024 EQUITY INCENTIVE COMPENSATION PLAN Section 1. Establishment and Purpose The purpose of the bioAffinity Technologies, Inc. 2024 Equity Incentive Compensation Plan (the “Plan”), is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers of bioAffinity Technologies, Inc. (the “Company”) and |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 4, 2024 Date of Report (Date of earliest event reported) bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commiss |
|
| June 5, 2024 |
As filed with the Securities and Exchange Commission on June 5, 2024 As filed with the Securities and Exchange Commission on June 5, 2024 Commission File No. |
|
| June 5, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF BIOAFFINITY TECHNOLOGIES, INC. bioAffinity Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Certificat |
|
| June 5, 2024 |
EXHIBIT 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) bioAffinity Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par valu |
|
| May 22, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-264463 PROSPECTUS SUPPLEMNT NO.1 4,305,813 Shares of Common Stock underlying Tradeable Warrants and Non-Tradeable Warrants and 55,116 Shares of Common Stock underlying Placement Agent Warrants and Representative’s Warrants bioAffinity Technologies, Inc. This prospectus supplement updates, amends and supplements the prospectus contained in our P |
|
| May 22, 2024 |
bioAffinity Technologies, Inc. 1,632,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-278512 PROSPECTUS SUPPLEMNT NO. 1 bioAffinity Technologies, Inc. 1,632,000 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus contained in our Amendment No. 1 to Form S-1, effective as of April 15, 2024 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333-278512). C |
|
| May 16, 2024 |
Exhibit 99.1 News Release bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes Expanded, experienced sales team more than doubles number of physician practices ordering CyPath® Lung test year-to-date More than 547% annualized growth rate for CyPath® Lung orders in first four months of 2024 over full-year 2023, leadi |
|
| May 16, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 001-41463 bioAffinit |
|
| April 17, 2024 |
bioAffinity Technologies, Inc. 1,632,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-278512 PROSPECTUS bioAffinity Technologies, Inc. 1,632,000 Shares of Common Stock This prospectus relates to the resale from time to time of up to 1,632,000 shares of common stock, par value $0.001 per share (the “Common Stock”), of bioAffinity Technologies, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholde |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 11, 2024 |
April 11, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 5, 2024 |
As filed with the Securities and Exchange Commission on April 5, 2024. As filed with the Securities and Exchange Commission on April 5, 2024. Registration No. 333-264463 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST - EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other j |
|
| April 4, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| April 4, 2024 |
As filed with the Securities and Exchange Commission on April 4, 2024. As filed with the Securities and Exchange Commission on April 4, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organizati |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 2, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024. As filed with the Securities and Exchange Commission on April 1, 2024. Registration No. 333-264463 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jur |
|
| April 1, 2024 |
Exhibit 3.3 Certificate of amendment of Certificate of incorporation of Bioaffinity technologies, inc. bioAffinity Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Certificat |
|
| April 1, 2024 |
Insider Trading Policy of the Registrant Exhibit 19.1 bioAffinity Technologies, Inc. Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities As Adopted by the Board of Directors on March 27, 2024 I. PURPOSE It is illegal for any employee, officer or director of bioAffinity Technologies, Inc. or any subsidiary thereof (the “Company”) to trade in the securities of the Company while in the possession |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| April 1, 2024 |
Exhibit 3.1 Certificate of incorporation of Bioaffinity technologies, inc. I, the undersigned, for the purpose of creating and organizing a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the “DGCL”), certify as follows: 1. The name of the corporation is bioAffinity Technologies, Inc. (the “Corporation”). 2. The address o |
|
| April 1, 2024 |
Exhibit 21.1 OncoSelect® Therapeutics, LLC, a Delaware limited liability company Precision Pathology Laboratory Services, LLC, a Texas limited liability company |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission file number 001-41463 bioAffinity Tech |
|
| April 1, 2024 |
Exhibit 4.13 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED bioAffinity Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.007 per share (the “Common Stock”), and trad |
|
| April 1, 2024 |
Exhibit 3.5 Certificate of amendment of Certificate of incorporation of Bioaffinity technologies, inc. bioAffinity Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Certificat |
|
| April 1, 2024 |
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results SAN ANTONIO, Texas (April 1, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease, today reported financial results for the three and 12 months ended December 31, 2023 |
|
| April 1, 2024 |
Exhibit 97.1 BIOAFFINITY TECHNOLOGIES, INC. CLAWBACK POLICY The Board of Directors (the “Board”) of bioAffinity Technologies, Inc. (the “Company”) has determined that it is in the best interests of the Company to adopt this Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy is |
|
| March 13, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| March 8, 2024 |
Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is made as of March 8, 2024, by and between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the beneficial owner of the number of shares of the common stock of the Company set forth oppo |
|
| March 8, 2024 |
Exhibit 99.2 bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement SAN ANTONIO, Texas (March 8, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) today announced it has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct |
|
| March 8, 2024 |
1,600,000 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-275608 EXPLANATORY NOTE: The purpose of this filing is to correct a typographical error in the Rule 424(b)(5) filing of bioAffinity Technologies, Inc. filed with the Securities and Exchange commission on March 8, 2024 (the “Original Prospectus”). The number of shares outstanding before and after the offering as set forth in the section entitled |
|
| March 8, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 8, 2024 |
Exhibit 99.1 bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement SAN ANTONIO, Texas (March 6, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| March 8, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of March 6, 2024, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECIT |
|
| March 8, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 8, 2024 |
1,600,000 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-275608 Prospectus Supplement (to Prospectus dated November 27, 2023) 1,600,000 Shares of Common Stock bioAffinity Technologies, Inc. We are offering 1,600,000 shares of our common stock, $0.007 par value per share (the “common stock”) directly to institutional investors pursuant to this prospectus supplement and the accompanying prospectus. The |
|
| March 8, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT March 6, 2024 bioAffinity Technologies Inc. 22211 W Interstate 10 Suite 1206 San Antonio, TX 78257 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,500,000 of registered and unregistered securities of the Co |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| March 5, 2024 |
Exhibit 99.1 bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung Increasing physician interest, newly approved reimbursement code driving growth SAN ANTONIO (March 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported accelerat |
|
| January 31, 2024 |
Exhibit 10.1 bioAffinity Technologies, Inc. MANAGEMENT INCENTIVE BONUS PLAN 1. BACKGROUND AND PURPOSE bioAffinity Technologies, Inc., a Delaware corporation, hereby adopts the Management Incentive Bonus Plan (the “Plan”), effective as provided in Paragraph 10. The purpose of the Plan is to align officers’ and other employees’ efforts with the strategic goals of the Company through competitive annu |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| January 31, 2024 |
Exhibit 10.2 AMENDMENT TO OFFER LETTER This Amendment (this “Amendment”), effective as of the 26th day of January 2024, to the Offer Letter, dated April 11, 2023 (the “Offer Letter”), by and between bioAffinity Technologies, Inc. (the “Company”) and Michael Dougherty (“Dougherty”). Capitalized terms used herein without definition shall have the meanings assigned in the Offer Letter. WHEREAS, the C |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| December 5, 2023 |
Exhibit 10.1 December 1, 2023 Dr. Jamie Platt [email protected] Dear Dr. Platt: As you know, bioAffinity Technologies is developing breakthrough technology for the early diagnosis of lung cancer and other diseases of the lung, as well as researching novel approaches for the treatment of cancer. Our Board of Directors plays a central role in our important work. I was pleased to learn of your |
|
| December 5, 2023 |
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors Exhibit 99.1 bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors SAN ANTONIO, Texas (Dec. 5, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today announced the appointment of Jamie Platt, Ph.D., to its Board of Directors effective De |
|
| November 30, 2023 |
Exhibit 99.1 CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024 SAN ANTONIO, Texas (Nov. 30, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (C |
|
| November 30, 2023 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| November 28, 2023 |
$25,000,000 BIOAFFINITY TECHNOLOGIES, INC. Common Stock Preferred Stock Debt Securities Filed Pursuant to Rule 424(b)(5) Registration No. 333-275608 PROSPECTUS $25,000,000 BIOAFFINITY TECHNOLOGIES, INC. Common Stock Preferred Stock Debt Securities Warrants Units We may, from time to time, offer and sell up to $25,000,000 of any combination of our common stock, preferred stock, debt securities, warrants or units described in this prospectus, either individually or in combination with |
|
| November 22, 2023 |
November 22, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 16, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) bioAffinity Technologies, Inc. |
|
| November 16, 2023 |
Exhibit 4.3 BIOAFFINITY TECHNOLOGIES, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 202 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.01 Designation and Terms of Securities 3 Section 2.02 Form of Securities and Trustee’s Certificate 5 |
|
| November 16, 2023 |
As filed with the Securities and Exchange Commission on November 16, 2023 As filed with the Securities and Exchange Commission on November 16, 2023 Registration Statement No. |
|
| November 15, 2023 |
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update SAN ANTONIO (Nov. 14, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and nine months ended Sept. |
|
| November 15, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 001-41463 bioAff |
|
| November 3, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2023 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction o |
|
| November 3, 2023 |
As filed with the Securities and Exchange Commission on November 3, 2023 As filed with the Securities and Exchange Commission on November 3, 2023 Commission File No. |
|
| October 18, 2023 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) bioAffinity Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par valu |
|
| October 18, 2023 |
As filed with the Securities and Exchange Commission on October 18, 2023 As filed with the Securities and Exchange Commission on October 18, 2023 Commission File No. |
|
| October 10, 2023 |
Investor Presentation of bioAffinity Technologies, Inc. dated October 2023 Exhibit 99.1 |
|
| October 10, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| October 10, 2023 |
BIAF / BioAffinity Technologies Inc / Joyce Roby Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* bioAffinity Technologies, Inc. (Name of Issuer) Common Stock, $0.007 par value per share (Title of Class of Securities) 09076W109 (CUSIP Number) Roby P. Joyce, M.D. c/o bioAffinity Technologies, Inc. 22211 W Interstate 10, Suite 1206 San Antonio, Texas 78 |
|
| October 10, 2023 |
Exhibit 99.2 bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference CEO Maria Zannes to hold one-on-one investor meetings and present a corporate update highlighting commercial strategy SAN ANTONIO, Texas (Oct. 10, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stag |
|
| September 25, 2023 |
22211 W Interstate 10 Suite 1206 San Antonio, Texas 78257 22211 W Interstate 10 Suite 1206 San Antonio, Texas 78257 September 22, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 20, 2023 |
Exhibit 10.7 ASSIGNMENT AND ASSUMPTION OF LEASE AGREEMENT THIS ASSIGNMENT AND ASSUMPTION OF LEASE AGREEMENT (this “Agreement”) is made and entered into to be effective as of 12:01 a.m. Central Time, September 18, 2023 (the “Effective Date”), by and between Village Oaks Pathology Services, P.A., a Texas professional association d/b/a Precision Pathology Services (“Assignor”), and Precision Patholog |
|
| September 20, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| September 20, 2023 |
Exhibit 4.2 AMENDMENT TO INITIAL PUBLIC OFFERING WARRANTS This AMENDMENT TO INITIAL PUBLIC OFFERING WARRANTS (this “Amendment”) is entered into as of September 17, 2023, by and between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), and [ ] (the “Holder”). WHEREAS, the Holder is the holder of the following warrants that were issued in connection with the Holder’s purchase o |
|
| September 20, 2023 |
Exhibit 4.1 AMENDMENT TO COMMON SHARE WARRANTS This AMENDMENT TO COMMON SHARE WARRANTS (this “Amendment”) is entered into as of September 17, 2023, by and between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), and [ ] (the “Holder”). WHEREAS, the Holder is the holder of the following Common Share Purchase Warrants (each, a “Warrant” and together the “Warrants”): (1) a Warr |
|
| September 20, 2023 |
Exhibit 10.12 STRATEGIC RELATIONSHIP AND LICENSE AGREEMENT This Strategic Relationship and License Agreement (this “Agreement”) is entered into December 1, 2022 (the “Effective Date”) by and between Precision Pathology Services, a Texas corporation with its principal location at 3300 Nacogdoches Rd #110, San Antonio, TX 78217 and Pathology Watch, Inc. (hereinafter “PW”), a Delaware corporation wit |
|
| September 20, 2023 |
Exhibit 3.5 Certificate of amendment of Certificate of incorporation of Bioaffinity technologies, inc. bioAffinity Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Certificat |
|
| September 20, 2023 |
Exhibit 3.3 Certificate of amendment of Certificate of incorporation of Bioaffinity technologies, inc. bioAffinity Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Certificat |
|
| September 20, 2023 |
Exhibit 3.1 Certificate of incorporation of Bioaffinity technologies, inc. I, the undersigned, for the purpose of creating and organizing a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the “DGCL”), certify as follows: 1. The name of the corporation is bioAffinity Technologies, Inc. (the “Corporation”). 2. The address o |
|
| September 20, 2023 |
Exhibit 10.8 OFFICE LEASE This Office Lease (the “Lease”), dated for reference purposes only as of July 31, 2019, is made by and between 343 West Sunset, LLC, a Texas limited liability company (“Landlord”), with an address of c/o Endura Advisory Group, 9311 San Pedro, Suite 850, San Antonio, Texas 78316, Attention: Property Manager, and Village Oaks Pathology Services, P.A., a Texas professional a |
|
| September 20, 2023 |
Exhibit 10.3 MANAGEMENT SERVICES AGREEMENT Table of contents Page ARTICLE I. ENGAGEMENT, EXCLUSIVITY AND RELATED MATTERS 1 1.1. Engagement 1 1.2. Exclusivity 2 1.3. Company Operations 2 1.4. Patient Referrals 2 ARTICLE II. RESPONSIBILITIES OF MANAGER 2 2.1. General 2 2.2. Billing and Collection 2 2.3. Power of Attorney 3 2.4. Accounting and Financial Services 3 2.5. Cash Management 4 2.6. Personne |
|
| September 20, 2023 |
Exhibit 10.4 SUCCESSION AGREEMENT THIS SUCCESSION AGREEMENT (this “Agreement”) is made, entered into and effective on and as of September 18, 2023 (the “Effective Date”), by and among Village Oaks Pathology Services, P.A., a Texas professional association (the “Practice”), Precision Pathology Laboratory Services, LLC, a Texas limited liability company (the “Company”), and Roby Joyce, M.D., a physi |
|
| September 20, 2023 |
Exhibit 10.11 |
|
| September 20, 2023 |
As filed with the Securities and Exchange Commission on September 20, 2023. As filed with the Securities and Exchange Commission on September 20, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organ |
|
| September 20, 2023 |
Exhibit 99.1 VILLAGE OAKS PATHOLOGY SERIVCES, P.A. D/B/A PRECISION PATHOLOGY SERVICES FINANCIAL STATEMENTS For the years ended December 31, 2022 and 2021 VILLAGE OAKS PATHOLOGY SERVICES, P.A. D/B/A PRECISION PATHOLOGY SERVICES TABLE OF CONTENTS INDEPENDENT AUDITOR’S REPORT 3 FINANCIAL STATEMENTS Balance Sheets as of December 31, 2022 and 2021 4 Statements of Operations for the years ended December |
|
| September 20, 2023 |
Exhibit 10.2 bioAffinity Technologies, Inc. SUBSCRIPTION AGREEMENT bioAffinity Technologies, Inc. Attn: Maria Zannes, Chief Executive Officer 22211 West I-10, Suite 1206 San Antonio, Texas 78257 To Whom It May Concern: You, the undersigned (the “Subscriber”), have been informed that bioAffinity Technologies, Inc., a Delaware corporation (“bioAffinity”), intends to offer (the “Offering”) to issue 5 |
|
| September 20, 2023 |
Exhibit 4.11 Form of Representative’s Warrant THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) |
|
| September 20, 2023 |
Exhibit 10.9 Assignment and Assumption Agreement This Assignment and Assumption Agreement (the “Agreement”), effective as of September 18, 2023 (the “Effective Date”), is by and between Village Oaks Pathology Services, P.A., a Texas professional association d/b/a Precision Pathology Services (“Seller”), and Precision Pathology Laboratory Services, LLC, a Texas limited liability company (“Buyer”). |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2023 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) ( |
|
| September 20, 2023 |
Form of Amendment to Common Share Purchase Warrants with schedule of warrant holders and warrants Exhibit 4.12 AMENDMENT TO COMMON SHARE WARRANTS This AMENDMENT TO COMMON SHARE WARRANTS (this “Amendment”) is entered into as of September 17, 2023, by and between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), and [ ] (the “Holder”). WHEREAS, the Holder is the holder of the following Common Share Purchase Warrants (each, a “Warrant” and together the “Warrants”): (1) a War |
|
| September 20, 2023 |
Form of Amendment to Initial Public Offering Warrants with schedule of warrant holders and warrants Exhibit 4.13 AMENDMENT TO INITIAL PUBLIC OFFERING WARRANTS This AMENDMENT TO INITIAL PUBLIC OFFERING WARRANTS (this “Amendment”) is entered into as of September 17, 2023, by and between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), and [ ] (the “Holder”). WHEREAS, the Holder is the holder of the following warrants that were issued in connection with the Holder’s purchase |
|
| September 20, 2023 |
Exhibit 10.5 PROFESSIONAL SERVICES AGREEMENT THIS PROFESSIONAL SERVICES AGREEMENT (the “Agreement”) is made and entered into effective as of September 18, 2023 (the “Effective Date”) by and between Precision Pathology Laboratory Services, LLC, a Texas limited liability company (“Company”), and Village Oaks Pathology Services, P.A., a Texas professional association (“Group”). WITNESSETH: WHEREAS, C |
|
| September 20, 2023 |
Exhibit 10.13 Bill of Sale (Permits) For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Village Oaks Pathology Services, P.A., a Texas professional association d/b/a Precision Pathology Services (“Seller”), pursuant to that certain Asset Purchase Agreement, dated as of September 18, 2023 (the “Purchase Agreement”), entered into by and between Seller and |
|
| September 20, 2023 |
Exhibit 10.10 |
|
| September 20, 2023 |
Exhibit 99.2 VILLAGE OAKS PATHOLOGY SERVICES, P.A. D/B/A PRECISION PATHOLOGY SERVICES UNAUDITED FINANCIAL STATEMENTS For the six months ended June 30, 2023 and 2022 VILLAGE OAKS PATHOLOGY SERVICES, P.A. D/B/A PRECISION PATHOLOGY SERVICES TABLE OF CONTENTS FINANCIAL STATEMENTS (Unaudited) Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022 2 Unaudited Statements of Operations for t |
|
| September 20, 2023 |
BIOAFFINITY TECHNOLOGIES, INC. UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS Exhibit 99.3 BIOAFFINITY TECHNOLOGIES, INC. UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS On September 18, 2023, Precision Pathology Laboratory Services, LLC (“PPLS”), a Texas limited liability company and wholly owned subsidiary of bioAffinity Technologies, Inc. (“bioAffinity”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Dr. Roby P. Joyce, M.D. (“Owner”) an |
|
| September 20, 2023 |
Exhibit 10.6 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (“Agreement”) is made and entered into as of this September 18, 2023 (the “Effective Date”), by and between bioAffinity Technologies, Inc., a Delaware corporation (“Company”) and Roby Joyce, M.D. (“Executive”). WHEREAS, the Company desires to employ Executive on the terms and conditions set forth herein; and WHEREAS, E |
|
| September 20, 2023 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT by and AMONG precision pathology laboratory services, LLC VILLAGE OAKS PATHOLOGY SERVICES, P.A., AND ROBY p. JOYCE, M.D. Effective as of September 18, 2023 TABLE OF CONTENTS Article 1 DEFINITIONS Article 2 PURCHASE OF NON-MEDICAL ASSETS 2.1 Purchase and Sale 1 2.2 Allocation 4 2.3 Assumed Liabilities 4 2.4 Excluded Assets 5 2.5 Excluded Liabilities 5 2.6 Fair |
